Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBM's Cash-to-Debt is ranked higher than
99% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CBM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.21 Max: No Debt
Current: No Debt
Equity-to-Asset 0.70
CBM's Equity-to-Asset is ranked higher than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBM: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
CBM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.75
Current: 0.7
0.22
0.75
Interest Coverage 99.92
CBM's Interest Coverage is ranked lower than
72% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBM: 99.92 )
Ranked among companies with meaningful Interest Coverage only.
CBM' s Interest Coverage Range Over the Past 10 Years
Min: 4.34  Med: 10.04 Max: 179.01
Current: 99.92
4.34
179.01
Piotroski F-Score: 8
Altman Z-Score: 7.91
Beneish M-Score: -2.09
WACC vs ROIC
19.16%
30.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 26.68
CBM's Operating Margin % is ranked higher than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CBM: 26.68 )
Ranked among companies with meaningful Operating Margin % only.
CBM' s Operating Margin % Range Over the Past 10 Years
Min: -2.77  Med: 12.14 Max: 26.68
Current: 26.68
-2.77
26.68
Net Margin % 17.70
CBM's Net Margin % is ranked higher than
87% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. CBM: 17.70 )
Ranked among companies with meaningful Net Margin % only.
CBM' s Net Margin % Range Over the Past 10 Years
Min: 3.18  Med: 10.67 Max: 82.87
Current: 17.7
3.18
82.87
ROE % 22.58
CBM's ROE % is ranked higher than
95% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CBM: 22.58 )
Ranked among companies with meaningful ROE % only.
CBM' s ROE % Range Over the Past 10 Years
Min: 8.97  Med: 17.12 Max: 120.02
Current: 22.58
8.97
120.02
ROA % 15.23
CBM's ROA % is ranked higher than
94% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CBM: 15.23 )
Ranked among companies with meaningful ROA % only.
CBM' s ROA % Range Over the Past 10 Years
Min: 2.22  Med: 8.84 Max: 42.71
Current: 15.23
2.22
42.71
ROC (Joel Greenblatt) % 37.45
CBM's ROC (Joel Greenblatt) % is ranked higher than
89% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CBM: 37.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1.19  Med: 16.08 Max: 38.19
Current: 37.45
-1.19
38.19
3-Year Revenue Growth Rate 13.10
CBM's 3-Year Revenue Growth Rate is ranked higher than
65% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CBM: 13.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 4.5 Max: 16
Current: 13.1
-18.1
16
3-Year EBITDA Growth Rate 25.80
CBM's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CBM: 25.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -32.1  Med: 9.7 Max: 66.1
Current: 25.8
-32.1
66.1
3-Year EPS without NRI Growth Rate 39.30
CBM's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CBM: 39.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -71.2  Med: 19.4 Max: 302.1
Current: 39.3
-71.2
302.1
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBM's 30-Y Financials

Financials (Next Earnings Date: 2017-11-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CBM Guru Trades in Q3 2016

Third Avenue Management 83,939 sh (+9.47%)
Steven Cohen 113,400 sh (+1.34%)
Jim Simons Sold Out
Paul Tudor Jones 6,734 sh (-6.00%)
Columbia Wanger 190,786 sh (-39.42%)
Chuck Royce 68,098 sh (-60.08%)
» More
Q4 2016

CBM Guru Trades in Q4 2016

Columbia Wanger 269,795 sh (+41.41%)
Paul Tudor Jones 8,182 sh (+21.50%)
Chuck Royce 81,598 sh (+19.82%)
Steven Cohen Sold Out
Third Avenue Management 83,585 sh (-0.42%)
» More
Q1 2017

CBM Guru Trades in Q1 2017

Jeremy Grantham 4,400 sh (New)
Jim Simons 191,800 sh (New)
Joel Greenblatt 27,978 sh (New)
Chuck Royce 119,598 sh (+46.57%)
Third Avenue Management 85,485 sh (+2.27%)
Paul Tudor Jones Sold Out
Columbia Wanger 146,076 sh (-45.86%)
» More
Q2 2017

CBM Guru Trades in Q2 2017

Columbia Wanger 833,486 sh (+470.58%)
Jim Simons 254,202 sh (+32.53%)
Jeremy Grantham 4,400 sh (unchged)
Joel Greenblatt Sold Out
Third Avenue Management 68,885 sh (-19.42%)
Chuck Royce 61,598 sh (-48.50%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Third Avenue Management 2017-06-30 Reduce -19.42%0.04%$51.4 - $60.9 $ 54.05-4%68,885
Joel Greenblatt 2017-06-30 Sold Out 0.02%$51.4 - $60.9 $ 54.05-4%0
Third Avenue Management 2017-03-31 Add 2.27%$49.75 - $58.25 $ 54.051%85,485
Joel Greenblatt 2017-03-31 New Buy0.02%$49.75 - $58.25 $ 54.051%27,978
Third Avenue Management 2016-12-31 Reduce -0.42%$38.85 - $54.85 $ 54.0513%83,585
Third Avenue Management 2016-09-30 Add 9.47%0.01%$42.83 - $58.85 $ 54.0511%83,939
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:NAS:ARRY, NAS:MYOK, NAS:RGEN, NAS:AKCA, NYSE:EBS, NAS:XLRN, NAS:INVA, NAS:CORT, NAS:INSM, NYSE:BHVN, NAS:LXRX, NAS:DVAX, NAS:IMMU, NAS:BPMC, NAS:FOLD, NAS:GBT, NAS:HALO, NAS:SGMO, NYSE:XON, NAS:SAGE » details
Traded in other countries:XBX.Germany,
Headquarter Location:USA
Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Cambrex is a biotechnology company focused on developing and commercializing new and generic therapeutics. The company primarily supplies its products and services worldwide to innovator and generic pharmaceutical companies. Cambrex's portfolio growth strategy has a particular focus on the later stages of the clinical trial process. It also works to secure long-term supply agreements to produce active pharmaceutical ingredients and intermediates for newly approved drug products. Additionally, Cambrex sometimes works with partners to codevelop portfolios of niche generic drug products in finished dosage form.

Guru Investment Theses on Cambrex Corp

Third Avenue Comments on Cambrex Corp - May 27, 2016

Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.


Cambrex is a well-financed specialty chemical company focused on life sciences; it develops and commercializes active pharmaceutical ingredients (APIs). Cambrex also produces Generic APIs, Controlled Substance APIs and is expanding into finished-dosage generic API manufacturing. Cambrex's API business is unique in that it manufactures the active ingredient in several leading pharmaceuticals and serves as a supplier to various drug companies. As such, it generates revenues from volumes sold and not price per finished pill. Cambrex's customers focus not only on product purity but also on quality, consistency and documentation of the manufacturing process ascompetitive attributes.


Several long-term drivers support revenue growth for Cambrex.



  1. Cambrex is a substantial beneficiary of the U.S. Federal Drug Administration's (FDA) significantly enhanced effort to ensure quality manufacturing processes. The company has benefitted as larger pharmaceutical companies have re-shored their API sourcing activities to "Western" Current Good Manufacturing Practice (CGMP) companies.

  2. Industry growth remains healthy, aided by the increasing number of small molecule drug developments and pending regulatory approvals in the U.S. and Europe.

  3. Pharmaceutical companies are continuing to reduce their own manufacturing activities and thus turning to outsourcing firms, such as Cambrex, to focus on new drug development.

Cambrex is in the midst of a capacity expansion in Charles City, Iowa that should drive significant revenue growth as this capacity is completed and filled for the next few years.



From Chip Rewey's second quarter 2016 Third Avenue Small-Cap Value Fund letter.



Check out Martin Whitman,Third Avenue Management latest stock trades

Top Ranked Articles about Cambrex Corp

Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility
Cambrex to Present at Upcoming Investor Conferences in September
Cambrex to Announce Second Quarter 2017 Financial Results on August 4, 2017
Cambrex to Present at the Jefferies 2017 Global Healthcare Conference
Cambrex to Present at the 2017 UBS Global Healthcare Conference
Cambrex to Announce First Quarter 2017 Financial Results on May 4, 2017
Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conference

EAST RUTHERFORD, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference on February 22, 2017 at 8:00 a.m. EST in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes. About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
IR Associate
Tel: 201 804 3037
Email: [email protected]

Read more...
Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017

EAST RUTHERFORD, N.J., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that fourth quarter and full year 2016 financial results will be released on Friday, February 3, 2017 before the market opens. The Company will host a conference call to discuss the financial results.   Fourth Quarter 2016 Earnings Conference Call   When: Friday, February 3, 2017 at 8:30 a.m. Eastern Time   Dial-in: 1-888-726-2470 for U.S.  1-913-312-0696 for International  Passcode:  9860937   Dial-in Replay: 1-888-203-1112 for U.S.  1-719-457-0820 for International  Passcode:  9860937  Available through Friday, February 10, 2017   Webcast: www.cambrex.com    About Cambrex Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
Investor Relations Associate
Tel: 201-804-3037
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 19.59
CBM's PE Ratio is ranked higher than
64% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CBM: 19.59 )
Ranked among companies with meaningful PE Ratio only.
CBM' s PE Ratio Range Over the Past 10 Years
Min: 1.05  Med: 16.48 Max: 59.25
Current: 19.59
1.05
59.25
Forward PE Ratio 15.90
CBM's Forward PE Ratio is ranked higher than
55% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. CBM: 15.90 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.31
CBM's PE Ratio without NRI is ranked higher than
68% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. CBM: 18.31 )
Ranked among companies with meaningful PE Ratio without NRI only.
CBM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.27  Med: 16.93 Max: 94.8
Current: 18.31
5.27
94.8
Price-to-Owner-Earnings 29.54
CBM's Price-to-Owner-Earnings is ranked lower than
63% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. CBM: 29.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CBM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.29  Med: 22.23 Max: 364.38
Current: 29.54
1.29
364.38
PB Ratio 3.76
CBM's PB Ratio is ranked lower than
57% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CBM: 3.76 )
Ranked among companies with meaningful PB Ratio only.
CBM' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.39 Max: 5.9
Current: 3.76
0.61
5.9
PS Ratio 3.47
CBM's PS Ratio is ranked higher than
76% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CBM: 3.47 )
Ranked among companies with meaningful PS Ratio only.
CBM' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.36 Max: 10.71
Current: 3.47
0.18
10.71
Price-to-Free-Cash-Flow 36.58
CBM's Price-to-Free-Cash-Flow is ranked lower than
86% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. CBM: 36.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CBM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 16.89 Max: 130.49
Current: 36.58
4.87
130.49
Price-to-Operating-Cash-Flow 18.87
CBM's Price-to-Operating-Cash-Flow is ranked lower than
55% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. CBM: 18.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CBM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.92  Med: 10.94 Max: 63.93
Current: 18.87
2.92
63.93
EV-to-EBIT 12.12
CBM's EV-to-EBIT is ranked higher than
68% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CBM: 12.12 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s EV-to-EBIT Range Over the Past 10 Years
Min: -119.9  Med: 11.8 Max: 306.6
Current: 12.12
-119.9
306.6
EV-to-EBITDA 10.07
CBM's EV-to-EBITDA is ranked higher than
68% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CBM: 10.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.8  Med: 8.3 Max: 35.9
Current: 10.07
-0.8
35.9
EV-to-Revenue 3.23
CBM's EV-to-Revenue is ranked higher than
79% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CBM: 3.23 )
Ranked among companies with meaningful EV-to-Revenue only.
CBM' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.1  Med: 1.5 Max: 13.1
Current: 3.23
-0.1
13.1
PEG Ratio 0.79
CBM's PEG Ratio is ranked higher than
74% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. CBM: 0.79 )
Ranked among companies with meaningful PEG Ratio only.
CBM' s PEG Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.19 Max: 7.88
Current: 0.79
0.48
7.88
Shiller PE Ratio 44.40
CBM's Shiller PE Ratio is ranked lower than
55% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. CBM: 44.40 )
Ranked among companies with meaningful Shiller PE Ratio only.
CBM' s Shiller PE Ratio Range Over the Past 10 Years
Min: 2.83  Med: 30.8 Max: 435.33
Current: 44.4
2.83
435.33
Current Ratio 4.15
CBM's Current Ratio is ranked lower than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CBM: 4.15 )
Ranked among companies with meaningful Current Ratio only.
CBM' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.59 Max: 5.19
Current: 4.15
0.9
5.19
Quick Ratio 2.37
CBM's Quick Ratio is ranked lower than
69% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CBM: 2.37 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.42 Max: 4.55
Current: 2.37
0.5
4.55
Days Inventory 176.57
CBM's Days Inventory is ranked lower than
65% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CBM: 176.57 )
Ranked among companies with meaningful Days Inventory only.
CBM' s Days Inventory Range Over the Past 10 Years
Min: 124.14  Med: 131.78 Max: 176.57
Current: 176.57
124.14
176.57
Days Sales Outstanding 69.96
CBM's Days Sales Outstanding is ranked higher than
64% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CBM: 69.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.84  Med: 63.9 Max: 82.29
Current: 69.96
49.84
82.29
Days Payable 48.29
CBM's Days Payable is ranked lower than
53% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CBM: 48.29 )
Ranked among companies with meaningful Days Payable only.
CBM' s Days Payable Range Over the Past 10 Years
Min: 37.86  Med: 51.72 Max: 63.55
Current: 48.29
37.86
63.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
CBM's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CBM: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.9  Med: -1.7 Max: 5.4
Current: -2
-15.9
5.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 10.81
CBM's Price-to-Net-Current-Asset-Value is ranked lower than
75% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CBM: 10.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.29  Med: 7.68 Max: 107.17
Current: 10.81
1.29
107.17
Price-to-Tangible-Book 4.28
CBM's Price-to-Tangible-Book is ranked lower than
53% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CBM: 4.28 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.33  Med: 3.39 Max: 14.12
Current: 4.28
0.33
14.12
Price-to-Intrinsic-Value-Projected-FCF 2.27
CBM's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
61% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. CBM: 2.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CBM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 2.05 Max: 46.39
Current: 2.27
0.7
46.39
Price-to-Median-PS-Value 2.56
CBM's Price-to-Median-PS-Value is ranked lower than
89% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CBM: 2.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.91 Max: 6.83
Current: 2.56
0.11
6.83
Price-to-Peter-Lynch-Fair-Value 0.77
CBM's Price-to-Peter-Lynch-Fair-Value is ranked higher than
83% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. CBM: 0.77 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CBM' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.13 Max: 8.25
Current: 0.77
0.54
8.25
Price-to-Graham-Number 1.87
CBM's Price-to-Graham-Number is ranked higher than
59% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. CBM: 1.87 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CBM' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.36  Med: 1.45 Max: 4.29
Current: 1.87
0.36
4.29
Earnings Yield (Greenblatt) % 8.23
CBM's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CBM: 8.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -136  Med: 7.9 Max: 209.9
Current: 8.23
-136
209.9
Forward Rate of Return (Yacktman) % 25.43
CBM's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. CBM: 25.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CBM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -35.4  Med: 8.7 Max: 25.6
Current: 25.43
-35.4
25.6

More Statistics

Revenue (TTM) (Mil) $516.83
EPS (TTM) $ 2.76
Beta2.85
Short Percentage of Float8.20%
52-Week Range $38.30 - 62.95
Shares Outstanding (Mil)32.73

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 541 593
EPS ($) 2.97 3.40
EPS without NRI ($) 2.97 3.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference Sep 18 2017 
Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Aug 30 2017 
Cambrex to Present at Upcoming Investor Conferences in September Aug 30 2017 
Cambrex to Announce Second Quarter 2017 Financial Results on August 4, 2017 Jul 31 2017 
Cambrex to Present at the Jefferies 2017 Global Healthcare Conference May 31 2017 
Cambrex to Present at the 2017 UBS Global Healthcare Conference May 15 2017 
Cambrex to Announce First Quarter 2017 Financial Results on May 4, 2017 May 01 2017 
Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 15 2017 
Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017 Feb 01 2017 
Third Avenue Comments on Cambrex Corp May 27 2016 

More From Other Websites
Is Cambrex Corporation (CBM) a Suitable Value Stock? Sep 19 2017
Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference Sep 18 2017
See what the IHS Markit Score report has to say about Cambrex Corp. Sep 12 2017
Cambrex to Present at Upcoming Investor Conferences in September Aug 30 2017
Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC... Aug 30 2017
Cleantech Building Materials: Unaudited Interim Results to 30 June 2017 Aug 25 2017
ETFs with exposure to Cambrex Corp. : August 21, 2017 Aug 21 2017
3 Top Stocks You Can Buy on Sale Aug 19 2017
Edited Transcript of CBM earnings conference call or presentation 4-Aug-17 12:30pm GMT Aug 15 2017
Corporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D... Aug 11 2017
Cambrex Corp. :CBM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017 Aug 10 2017
IHS Markit Score downgrades Cambrex Corp to 21 out of 100, ranking positively in only one out of... Aug 10 2017
Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : August 8, 2017 Aug 08 2017
Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity at Its Charles City,... Aug 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}